Spots Global Cancer Trial Database for A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
Official Title: A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant, Administered in Combination With ZOFRAN and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-Based Chemotherapy
Study ID: NCT00431236
Study Description
Brief Summary: This is a Phase III trial designed to demonstrate that casopitant when added to dexamethasone and ondansetron is more effective in the prevention of vomiting then dexamethasone and ondansetron alone, in patients who receive a cisplatin-based highly emetogenic chemotherapy.
Detailed Description: A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant, administered in Combination with ZOFRAN and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-Based Chemotherapy
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GSK Investigational Site, Capital Federal, Buenos Aires, Argentina
GSK Investigational Site, Cordoba, Córdova, Argentina
GSK Investigational Site, Rosario, Santa Fe, Argentina
GSK Investigational Site, Tucuman, , Argentina
GSK Investigational Site, Edegem, , Belgium
GSK Investigational Site, Leuven, , Belgium
GSK Investigational Site, Liège, , Belgium
GSK Investigational Site, Sofia, , Bulgaria
GSK Investigational Site, Varna, , Bulgaria
GSK Investigational Site, Zagreb, , Croatia
GSK Investigational Site, Zagreb, , Croatia
GSK Investigational Site, Zagreb, , Croatia
GSK Investigational Site, Brno, , Czechia
GSK Investigational Site, Brno, , Czechia
GSK Investigational Site, Jihlava, , Czechia
GSK Investigational Site, Ostrava, , Czechia
GSK Investigational Site, Praha 5, , Czechia
GSK Investigational Site, Tabor, , Czechia
GSK Investigational Site, Helsinki, , Finland
GSK Investigational Site, Kangasala, , Finland
GSK Investigational Site, Turku, , Finland
GSK Investigational Site, Athens, , Greece
GSK Investigational Site, Kavala, , Greece
GSK Investigational Site, Papagos, Athens, , Greece
GSK Investigational Site, Thessaloniki, , Greece
GSK Investigational Site, Thessaloniki, , Greece
GSK Investigational Site, Budapest, , Hungary
GSK Investigational Site, Mátraháza, , Hungary
GSK Investigational Site, Székesfehérvár, , Hungary
GSK Investigational Site, Kochi, , India
GSK Investigational Site, Tirupati, , India
GSK Investigational Site, Dublin, , Ireland
GSK Investigational Site, Tallaght, Dublin, , Ireland
GSK Investigational Site, Wilton, Cork, , Ireland
GSK Investigational Site, Monteforte Irpino, Campania, Italy
GSK Investigational Site, Roma, Lazio, Italy
GSK Investigational Site, Roma, Lazio, Italy
GSK Investigational Site, Sassari, Sardegna, Italy
GSK Investigational Site, Pisa, Toscana, Italy
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Kubang Kerian, , Malaysia
GSK Investigational Site, Penang, , Malaysia
GSK Investigational Site, Sarawak, , Malaysia
GSK Investigational Site, Islamabad, , Pakistan
GSK Investigational Site, Karachi, , Pakistan
GSK Investigational Site, Karachi, , Pakistan
GSK Investigational Site, Lahore, , Pakistan
GSK Investigational Site, Lahore, , Pakistan
GSK Investigational Site, Baguio City, Benguet, , Philippines
GSK Investigational Site, Manila, , Philippines
GSK Investigational Site, Quezon City, , Philippines
GSK Investigational Site, Bialystok, , Poland
GSK Investigational Site, Bydgoszcz, , Poland
GSK Investigational Site, Krakow, , Poland
GSK Investigational Site, Olsztyn, , Poland
GSK Investigational Site, Poznan, , Poland
GSK Investigational Site, Poznan, , Poland
GSK Investigational Site, Bucuresti, , Romania
GSK Investigational Site, Iasi, , Romania
GSK Investigational Site, Timisoara, , Romania
GSK Investigational Site, Banska Bystrica, , Slovakia
GSK Investigational Site, Bratislava, , Slovakia
GSK Investigational Site, Poprad, , Slovakia
GSK Investigational Site, Avila, , Spain
GSK Investigational Site, Badalona, , Spain
GSK Investigational Site, Madrid, , Spain
GSK Investigational Site, Murcia, , Spain
GSK Investigational Site, Valencia, , Spain
GSK Investigational Site, Taichung, , Taiwan
GSK Investigational Site, Taichung, , Taiwan
GSK Investigational Site, TaoYuan Hsien, , Taiwan
GSK Investigational Site, Bangkok, , Thailand
GSK Investigational Site, Chiang Mai, , Thailand
GSK Investigational Site, Kharkiv, , Ukraine
GSK Investigational Site, Kyiv, , Ukraine
GSK Investigational Site, Lvov, , Ukraine
GSK Investigational Site, Sympheropol, , Ukraine
GSK Investigational Site, Uzhgorod, , Ukraine
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
